Peer-reviewed veterinary case report
Small animal Review
- Journal:
- Companion Animal
- Year:
- 2020
- Authors:
- Tennant, Bryn
- Affiliation:
- MRCVS Capital Diagnostics, SRUC Veterinary Services
- Species:
- dog
Plain-English summary
This study looked at how to manage allergic skin conditions in dogs, which can be treated with various medications, including oclacitinib. Oclacitinib works by blocking certain proteins that cause inflammation, but it may also affect how cells grow and survive. The researchers wanted to find out if using oclacitinib for a long time could increase the risk of cancer in dogs. The results of the study regarding this risk are still unclear.
Abstract
Summary: Allergic dermatitis in dogs can be managed using a range of medical therapies including glucocorticoids, ciclosporin, oclacitinib, loviketmab and immunotherapy. Oclacitinib inhibits janus-kinases leading to depressed function of proinflammatory cytokines. Some cytokines protect against tumour development. Oclacitinib may hinder cell proliferation, differentiation, migration, apoptosis and survival. Oclacitinib's impact in dogs who have neoplasia is unclear. The study discussed here has assessed the risk of neoplasia in dogs treated over a long period with oclacitinib.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://doi.org/10.12968/coan.2020.0083